Patent Granted for MoAbs Used in Neoprobe's RIGScan Products

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 7
Volume 5
Issue 7

DUBLIN, Ohio--Neoprobe Corporation has announced that a patent granted to Jeffrey Schlom, PhD, of the National Cancer Institute, and David Colcher, PhD, of the University of Nebraska Medical Center, covers claims to composition of matter for a large group of second-generation monoclonal antibodies that target the tumor-associated antigen TAG-72.

DUBLIN, Ohio--Neoprobe Corporation has announced that a patentgranted to Jeffrey Schlom, PhD, of the National Cancer Institute,and David Colcher, PhD, of the University of Nebraska MedicalCenter, covers claims to composition of matter for a large groupof second-generation monoclonal antibodies that target the tumor-associatedantigen TAG-72.

Neoprobe holds an exclusive global license for use of these antibodieswith its RIGS technology for surgical detection and treatmentof cancer. The antibodies named in the patent include CC49, acomponent of Neo-probe's first commercial product, RIGScan CR49,currently under investigation for colorectal cancer.

Related Videos
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey Anders, MD, an expert on breast cancer
Carey K. Anders, MD, an expert on breast cancer
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
A panel of 4 experts on breast cancer seated at a long table
The use of a single-port robot may allow for surgically treating more patients with head and neck cancer in a more timely manner, according to Hilary McCrary, MD, MPH.
A panel of 5 experts on colorectal cancer
A panel of 5 experts on colorectal cancer
Related Content